• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Onn, A
    Tsuboi, M
    Thatcher, Nick
    Affiliation
    Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Box 403, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. amironn@mdanderson.org
    Issue Date
    2004-08
    
    Metadata
    Show full item record
    Abstract
    Worldwide, non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality and, until screening detects early disease, treatment for the majority of patients will consist of radiation therapy, chemotherapy or combinations thereof. Modern mono and doublet chemotherapy regimens have translated into modest increases in life expectancy and improved quality of life, but at the expense of systemic and pulmonary adverse events (AEs). There is a great unmet need to provide effective therapy for advanced NSCLC that does not have the toxicity burden of conventional chemotherapy and radiotherapy. Novel drugs that inhibit a range of growth factor receptors, such as the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib ('Iressa') and erlotinib ('Tarceva') or the monoclonal antibody cetuximab ('Erbitux'), have recently been evaluated. Having demonstrated antitumour activity and rapid symptom improvement in pretreated patients with advanced NSCLC, gefitinib was approved in the USA, Japan and other countries. Gefitinib is well tolerated with a low incidence of grade 3/4 AEs. Interstitial lung disease has been reported in a small number of patients receiving gefitinib, although this may be attributed to other treatments and conditions. Nevertheless, although the use of novel treatments requires vigilance for unexpected AEs such as pulmonary toxicity, in this area of high unmet clinical need, the benefits outweigh the risks in patients for whom no other proven effective treatment exists.
    Citation
    Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. 2004, 91 Suppl 2:S11-7 Br. J. Cancer
    Journal
    British Journal of Cancer
    URI
    http://hdl.handle.net/10541/77864
    DOI
    10.1038/sj.bjc.6602062
    PubMed ID
    15340373
    Type
    Article
    Language
    en
    ISSN
    0007-0920
    ae974a485f413a2113503eed53cd6c53
    10.1038/sj.bjc.6602062
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
    • Authors: Blackledge G, Averbuch S
    • Issue date: 2004 Feb 9
    • First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    • Authors: Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA
    • Issue date: 2016 May 25
    • Gefitinib therapy for non-small cell lung cancer.
    • Authors: Birnbaum A, Ready N
    • Issue date: 2005 Jan
    • Perspectives on salvage therapy for non-small-cell lung cancer.
    • Authors: Cappuzzo F, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G, Crinò L
    • Issue date: 2005 Jul
    • The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    • Authors: Evans WK, Kocha W, Gagliardi A, Eady A, Newman TE
    • Issue date: 1999 Feb
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.